Technical Analysis for APRE - Aprea Therapeutics, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
NR7 | Range Contraction | 0.00% | |
Narrow Range Bar | Range Contraction | 0.00% | |
Gapped Down | Weakness | 0.00% | |
MACD Bullish Signal Line Cross | Bullish | -1.47% | |
NR7 | Range Contraction | -1.47% | |
NR7-2 | Range Contraction | -1.47% | |
Gapped Up | Strength | -1.47% | |
NR7 | Range Contraction | 0.25% | |
Gapped Up | Strength | 0.25% | |
Shooting Star Candlestick | Bearish | -2.89% |
Alert | Time |
---|---|
Fell Below Previous Day's Low | about 5 hours ago |
Down 1% | about 5 hours ago |
Possible NR7 | about 5 hours ago |
10 DMA Support | 3 days ago |
Rose Above Previous Day's High | 3 days ago |
Get this analysis on your stocks daily!
- Earnings date: 08/08/2024
Aprea Therapeutics, Inc. Description
Aprea Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of novel anticancer compounds that reactivate the tumor suppressor protein, p53. The company's lead drug candidate APR-246, a small molecule p53 reactivator, is in clinical development for myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), as well as additional hematologic and solid tumor malignancies. It has commenced a Phase 3 clinical trial in p53 mutant MDS and completed enrollment in a Phase 1b/2 clinical trial in p53 mutant MDS and AML with APR-246 and azacitidine; and additional Phase 1/2 trials of APR-246 in MDS and AML in combination with approved anti-cancer therapies, as well as developing next generation p53 reactivators. The company was founded in 2003 and is based in Boston, Massachusetts.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Clinical Development Tumor Acute Myeloid Leukemia Cancer Therapies Myelodysplastic Syndrome Syndromes P53 Tumor Suppressor Genes Anti Cancer Therapies Tumor Suppressor
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 8.8465 |
52 Week Low | 2.78 |
Average Volume | 9,991 |
200-Day Moving Average | 5.07 |
50-Day Moving Average | 4.87 |
20-Day Moving Average | 4.30 |
10-Day Moving Average | 4.09 |
Average True Range | 0.26 |
RSI (14) | 34.64 |
ADX | 23.61 |
+DI | 13.23 |
-DI | 20.29 |
Chandelier Exit (Long, 3 ATRs) | 4.21 |
Chandelier Exit (Short, 3 ATRs) | 4.64 |
Upper Bollinger Bands | 4.80 |
Lower Bollinger Band | 3.80 |
Percent B (%b) | 0.23 |
BandWidth | 23.44 |
MACD Line | -0.27 |
MACD Signal Line | -0.29 |
MACD Histogram | 0.017 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 4.14 | ||||
Resistance 3 (R3) | 4.13 | 4.08 | 4.12 | ||
Resistance 2 (R2) | 4.08 | 4.05 | 4.09 | 4.12 | |
Resistance 1 (R1) | 4.06 | 4.03 | 4.07 | 4.07 | 4.11 |
Pivot Point | 4.01 | 4.01 | 4.01 | 4.01 | 4.01 |
Support 1 (S1) | 3.98 | 3.98 | 3.99 | 3.99 | 3.95 |
Support 2 (S2) | 3.93 | 3.96 | 3.94 | 3.94 | |
Support 3 (S3) | 3.91 | 3.93 | 3.94 | ||
Support 4 (S4) | 3.92 |